What happens if biomarker tests spot Alzheimer’s before people show symptoms?
By
Kristen Fischer
Aug 05, 2024
As of now, no therapy is approved by the Food and Drug Administration for people at risk of Alzheimer’s disease who don’t have symptoms. But blood tests that can spot biomarkers linked to the disease...
Plasma biomarkers of Alzheimer’s neuropathy linked to dementia risk
Aug 01, 2024
Significant associations were seen for all Alzheimer’s disease plasma biomarkers in late life with late-life dementia.
Nightmares in midlife may point to future cognitive decline, dementia
Jul 12, 2024
The findings were seen in middle-aged and older adults from the general population who did not have Parkinson’s disease.
Simple cognitive test and EMR tool boost dementia care actions in primary care setting, trial finds
By
Kristen Fischer
Jun 07, 2024
A five-minute cognitive assessment test and an electronic medical record (EMR) decision-making add-on system improved dementia diagnosis and care, according to a clinical trial.
Smartphone apps validated as method for detecting Alzheimer’s, new study shows
By
Aaron Dorman
Apr 02, 2024
A smartphone app with memory tests did just as well detecting MCI as when seniors took an in-person medical examination, new research shows.
Smartphone-based measures can help ID frontotemporal lobar degeneration
Apr 01, 2024
Individuals with frontotemporal lobar degeneration were accurately differentiated from controls with smartphone tests.
More news for Tuesday, March 12
By
Kimberly Bonvissuto
Mar 12, 2024
DOJ’s new whistleblower rewards program will seek to uncover more corporate misconduct … HUD Secretary Marcia Fudge announces resignation … California launches new campaign to ‘Take on Alzheimer’s’...
Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
Multiple sclerosis linked to lower risk for Alzheimer’s disease pathology
By
Haymarket Media
Aug 30, 2024
A lower rate of amyloid-β plasma biomarker positivity was seen in multiple sclerosis patients compared with non-MS controls.
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.